Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Research output: Contribution to journalJournal articleResearchpeer-review

  1. A small change makes a big difference in Hodgkin lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Treatment dilemmas in asymptomatic children with primary hemophagocytic lymphohistiocytosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Epigenetic therapy in hematological cancers

    Research output: Contribution to journalReviewResearchpeer-review

  2. Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The main objective of the MCL3 study was to improve outcome for patients not in complete remission (CR) before transplant by adding (90)Y-ibritumomab-tiuxetan (Zevalin) to the high-dose regimen. One hundred sixty untreated, stage II-IV mantle cell lymphoma patients <66 years received rituximab (R)-maxi-CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) alternating with R-high-dose cytarabine (6 cycles total), followed by high-dose BEAM/C (bis-chloroethylnitrosourea, etoposide, cytarabine, and melphalan or cyclophosphamide) and autologous stem cell transplantation from 2005 to 2009. Zevalin (0.4 mCi/kg) was given to responders not in CR before transplant. Overall response rate pretransplant was 97%. The outcome did not differ from that of the historic control: the MCL2 trial with similar treatment except for Zevalin. Overall survival (OS), event-free survival (EFS), and progression-free survival (PFS) at 4 years were 78%, 62%, and 71%, respectively. For responding non-CR patients who received Zevalin, duration of response was shorter than for the CR group. Inferior PFS, EFS, and OS were predicted by positron emission tomography (PET) positivity pretransplant and detectable minimal residual disease (MRD) after transplant. In conclusion, positive PET and MRD were strong predictors of outcome. Intensification with Zevalin may be too late to improve the outcome of patients not in CR before transplant. This trial was registered at www.clinicaltrials.gov as #NCT00514475.

Original languageEnglish
JournalBlood
Volume123
Issue number19
Pages (from-to)2953-9
Number of pages7
ISSN0006-4971
DOIs
Publication statusPublished - 8 May 2014

ID: 44355577